These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 3298065

  • 1. Mycobacterium bovis BCG-induced protection against cutaneous and systemic Leishmania major infections of mice.
    Fortier AH, Mock BA, Meltzer MS, Nacy CA.
    Infect Immun; 1987 Jul; 55(7):1707-14. PubMed ID: 3298065
    [Abstract] [Full Text] [Related]

  • 2. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63.
    Connell ND, Medina-Acosta E, McMaster WR, Bloom BR, Russell DG.
    Proc Natl Acad Sci U S A; 1993 Dec 15; 90(24):11473-7. PubMed ID: 8265576
    [Abstract] [Full Text] [Related]

  • 3. The role of IL-32 in Bacillus Calmette-Guérin (BCG)-induced trained immunity in infections caused by different Leishmania spp.
    Silva MVT, Dos Santos JC, Figueiredo AMB, Teufel LU, Pereira JX, Matos GG, Pinto SA, Netea MG, Gomes RS, Joosten LAB, Ribeiro-Dias F.
    Microb Pathog; 2021 Sep 15; 158():105088. PubMed ID: 34260904
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of anti-leishmanial effects of killed Leishmania vaccine with BCG adjuvant in BALB/c mice infected with Leishmania major MRHO/IR/75/ER.
    Nahrevanian H, Jafary SP, Nemati S, Farahmand M, Omidinia E.
    Folia Parasitol (Praha); 2013 Feb 15; 60(1):1-6. PubMed ID: 23539946
    [Abstract] [Full Text] [Related]

  • 5. Effect of a single exposure to ultraviolet radiation on Mycobacterium bovis bacillus Calmette-Guerin infection in mice.
    Jeevan A, Kripke ML.
    J Immunol; 1989 Nov 01; 143(9):2837-43. PubMed ID: 2681417
    [Abstract] [Full Text] [Related]

  • 6. Leishmania major infection in BALB/c mice: protection or exacerbation by treatment with different doses of BCG.
    Stefani MM, Müller I, Louis J.
    Res Immunol; 1993 May 01; 144(4):233-43. PubMed ID: 8378590
    [Abstract] [Full Text] [Related]

  • 7. Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major.
    Belosevic M, Finbloom DS, Van Der Meide PH, Slayter MV, Nacy CA.
    J Immunol; 1989 Jul 01; 143(1):266-74. PubMed ID: 2499629
    [Abstract] [Full Text] [Related]

  • 8. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes.
    Scott P, Pearce E, Natovitz P, Sher A.
    J Immunol; 1987 Jul 01; 139(1):221-7. PubMed ID: 3495599
    [Abstract] [Full Text] [Related]

  • 9. Immunization of BALB/c mice with mIFN-gamma-secreting Mycobacterium bovis BCG provides early protection against Leishmania major infection.
    Kong D, Belosevic M, Kunimoto DY.
    Int J Parasitol; 1997 Mar 01; 27(3):349-53. PubMed ID: 9138039
    [Abstract] [Full Text] [Related]

  • 10. Distinctive cellular immunity in genetically susceptible BALB/c mice recovered from Leishmania major infection or after subcutaneous immunization with killed parasites.
    Liew FY, Dhaliwal JS.
    J Immunol; 1987 Jun 15; 138(12):4450-6. PubMed ID: 3295049
    [Abstract] [Full Text] [Related]

  • 11. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in infected mice.
    Kohama H, Umemura M, Okamoto Y, Yahagi A, Goga H, Harakuni T, Matsuzaki G, Arakawa T.
    Vaccine; 2008 Feb 13; 26(7):924-32. PubMed ID: 18192091
    [Abstract] [Full Text] [Related]

  • 12. Immunoregulatory pathways in murine leishmaniasis: different regulatory control during Leishmania mexicana mexicana and Leishmania major infections.
    Alexander J, Kaye PM.
    Clin Exp Immunol; 1985 Sep 13; 61(3):674-82. PubMed ID: 3907906
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antileishmanial activities of macrophages from C3H/HeN and C3H/HeJ mice treated with Mycobacterium bovis strain BCG.
    Pappas MG, Nacy CA.
    Cell Immunol; 1983 Sep 13; 80(2):217-22. PubMed ID: 6349826
    [Abstract] [Full Text] [Related]

  • 19. A strategy to improve the efficacy of vaccination against tuberculosis and leprosy.
    Bretscher PA.
    Immunol Today; 1992 Sep 13; 13(9):342-5. PubMed ID: 1466750
    [Abstract] [Full Text] [Related]

  • 20. Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis.
    Aldwell FE, Cross ML, Fitzpatrick CE, Lambeth MR, de Lisle GW, Buddle BM.
    Vaccine; 2006 Mar 15; 24(12):2071-8. PubMed ID: 16332403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.